Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of YM150 in Non-Valvular Atrial Fibrillation
2006-004761-34Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darexaban in Atrial fibrillation (AFib) and stroke (2 arms), sponsored by Astellas Pharma. Started Feb 2007; status: terminated.
02
Drugs
darexaban
03
Conditions
Atrial fibrillation (AFib)stroke
Beyond the preview
Go deeper on 2006-004761-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004761-34.